Ajanta Pharma Ltd. News and Updates

Name: Latest research reports of Ajanta Pharma Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Ajanta Pharma Ltd. from all sources in a single place.

Load latest

Ajanta Pharma Ltd.

01 Aug 2023

2622.50

0.78%

Buy Ajanta Pharma; target of Rs 1580: ICICI Securities

Moneycontrol

ICICI Securities is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 1580 in its research report dated July 29, 2023.

Ajanta Pharma Ltd. is trading below its 50 day SMA of 2680.2

Buy Ajanta Pharma; target of Rs 1800: Motilal Oswal

Moneycontrol | 31 Jul 2023

Ajanta Pharma Ltd.

29 Jul 2023

2622.50

0.78%

Margin improvement story unfolding

Buy: Ajanta Pharma Ltd.

ICICI Securities Limited

Ajanta Pharma’s Q1FY24 result surprised positively on margin front. Softening of raw material and freight costs have started showing improvement in gross (+482bps YoY) and EBITDA (+325bps) margins. Traction in India branded business continues to be robust, with 14% growth vs market growth rate of 9%, while momentum in export branded business is expected to gain in quarters ahead.

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

28 Jul 2023

2622.50

0.78%

Ajanta Pharma's shares surge by 9.55%

Business Line

The company's revenue was up 7.37 per cent to 1,021.04 crore compared to 950.93 crore last year

Ajanta Pharma Ltd. is trading below its 50 day SMA of 2680.2

Ajanta Pharma share price surges 9% to a 52-week high after Q1 results; what should investors do?

livemint | 28 Jul 2023 2 more

Ajanta Pharma Ltd.

28 Jul 2023

2622.50

0.78%

to see Rapid results content

Ajanta Pharma Ltd.

28 Jul 2023

2622.50

0.78%

Ajanta Pharma (BUY): Q1 beat sparked by sharp margin recovery

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Strong Q1 beat with EBITDA/PAT of Rs 2.7bn/Rs 2.1bn coming in 17%/ 39% ahead of consensus due to margin recovery

Ajanta Pharma Ltd. is trading below its 50 day SMA of 2680.2

Ajanta Pharma Ltd.

28 Jul 2023

2622.50

0.78%

Ajanta Pharma

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Ajanta Pharma Ltd. is trading above its 30 day SMA of 2595.6

Ajanta Pharma Ltd.

12 Jul 2023

2622.50

0.78%

Ajanta Pharma Q1 PAT seen up 9.1% YoY to Rs 190.5 cr: Nirmal Bang

Moneycontrol

Net Sales are expected to increase by 9.6 percent Y-o-Y (up 18.2 percent Q-o-Q) to Rs 1,042.3 crore, according to Nirmal Bang.

Ajanta Pharma Ltd. is trading above its 30 day SMA of 2595.6

Ajanta Pharma Ltd.

02 Jul 2023

2622.50

0.78%

Ajanta Pharma looks to expand ops in high-growth Asian, African geographies

Business Standard

As part of its growth plans, Ajanta Pharma is looking to enhance its presence across select geographies with high growth potential in Asia and Africa. In its Annual Report for 2022-23, the Mumbai-based drug maker stated that it intends to rely on its strengths to grow faster in countries where it has a presence with its range of branded generics. "As we achieve formidable positions in many markets, our strategy now entails enhancing focus on select countries from our geographical presence, which promises high growth potential," Ajanta Pharma informed its shareholders. These territories offer a large branded generics pharma market size, but the company's presence still remains small, it added. "We plan to ramp up our presence in these markets and add value to the patients' choices through our differentiated product portfolio," the drug firm said. The company's branded generics business accounted for 73 per cent of its revenues in FY 2023, with Indian, rest of Asia and Africa...

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

26 Jun 2023

2622.50

0.78%

Ajanta Pharma gets US FDA observations after inspection at Dahej facility

livemint

United States Food and Drug Administration issued Form 483 to Ajanta Pharma limited after the successful completion of its audit of Ajanta Pharma's Dahej facility

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

22 Jun 2023

2622.50

0.78%

Ajanta Pharma hits 52-week high on upbeat branded generic business outlook

Business Standard

The management is confident to scale up margins again in the coming years on the back of enhanced contribution from Branded Generics business and normalisation of freight costs